Relates to the administration of reversible progestin-only contraceptive injections; provides that no pharmacist shall administer reversible progestin-only contraceptive injections without receiving training satisfactory to the commissioner of education and the commissioner of health.
A08664 would amend the Education Law to authorize licensed pharmacists in New York to administer reversible progestin-only contraceptive injections, such as depot-style birth control shots, when prescribed or ordered by a licensed prescriber and when the pharmacist is acting within the scope of practice and any regulations issued by the commissioner. The bill requires that the administration be based on a valid patient-specific prescription or order, and it limits pharmacy administration to patients who have already received the initial injection and are eligible for maintenance treatment.
The bill also sets out communication and safety requirements. Pharmacists must notify the prescriber within five days that the injection was administered, or notify the prescriber if the patient did not receive the injection or experienced side effects or adverse reactions. The bill allows notification through electronic medical records, e-prescribing systems, pharmacy records, fax, electronic transmission, telephone, or other electronic means if available. It also requires that injections in a pharmacy be given in a private area and that pharmacists be trained in screening, informed consent, administration techniques, contraindications, recordkeeping, and emergency response, including anaphylaxis and needlesticks.
This bill would expand the scope of pharmacy practice in New York by expressly adding reversible progestin-only contraceptive injections to the list of injectable medications pharmacists may administer after completing required training and obtaining a certificate of administration. It would also amend existing Education Law provisions governing pharmacist administration of immunizing agents and certain injectable medications, while preserving oversight by the commissioner of education and the commissioner of health through training and regulatory standards. In practical terms, it would increase access points for contraceptive care and create new compliance obligations for pharmacists, prescribers, and pharmacies.
The available voting history suggests generally favorable sentiment toward the bill, with the Assembly Higher Education Committee reporting 24 yeas and 2 nays and advancing it to Rules. The bill text and caption indicate a public-health and access-to-care purpose, and the committee action implies broad support for allowing pharmacists to play a larger role in contraceptive administration. No committee transcript was provided, so the record does not show detailed debate, but the vote indicates the measure was not highly divisive at the committee stage.
The main points of contention likely center on expanding pharmacist authority to administer hormonal contraception, including concerns about training adequacy, patient safety, informed consent, privacy, and coordination with prescribers. The bill addresses some of these issues by requiring commissioner-approved training, patient-specific orders, prescriber notification, and private administration space. Any opposition appears limited in the available record, as reflected by only two nays in committee, but the subject matter may still raise concerns among those wary of broadening pharmacy practice or shifting reproductive-health services away from traditional clinical settings.